Phase 4
Completed N=10
Effect of Bupropion on Seizure Threshold in Depressed Patients
MDD
Source: ClinicalTrials.gov NCT03126682 ↗
Enrolled (actual)
10
Serious AEs
0.0%
Results posted
Jul 2019
Primary outcomePrimary: Change in Seizure Threshold — 23.04; 19.68 millicoulombs
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The purpose of the study is to examine the effect of bupropion on seizure threshold and duration in depressed patients receiving right unilateral ultra-brief electroconvulsive therapy (ECT). The investigators plan to recruit 10 patients into the study, administer sustained release (SR) bupropion 4 hours prior to receiving ECT. The investigators plan to compare the seizure threshold and seizure durations between ECT sessions with and without bupropion administration. The study's implication is to examine how ECT can be optimized by rational combination with medications that lower seizure threshold.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Seizure Threshold |
23.04; 19.68 | — |
| PRIMARY Change in Seizure Duration |
26.2; 29.6 | — |
| SECONDARY Change in MADRS Score |
2.60; 3.60 | 0.212 |
Eligibility Criteria
Inclusion Criteria
- Male and female subjects, age >18.
- Meeting diagnostic criteria for major depressive disorder or bipolar disorder per DSM5.
- Referred for ultra brief RUL ECT.
- Right motor dominant.
- Competent to provide informed consent.
- Able to read or comprehend English.
- H/O treatment with bupropion.
- Concomitant treatment with benzodiazepines, dosing of which has remained stable for a week prior to study ECT session.
Exclusion Criteria
- Lifetime history of schizophrenia, schizoaffective disorder, mental retardation, seizure disorder.
- Current alcohol abuse or dependence within past 6 months.
- Current substance abuse or dependence within past 6 months.
- Recently received ECT within preceding 3-6 months.
- Currently on any formulation of bupropion.
- Currently on any anticonvulsants or clozapine.
Data sourced from ClinicalTrials.gov (NCT03126682). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.